Beckman Coulter
This article was originally published in The Gray Sheet
Executive Summary
Firm has no plans to enter coagulation self-testing market following purchase of the CLIA-waived AvoSure hand-held device from Avocet Medical for $3 mil., announced Jan. 7. The AvoSure received FDA clearance in 1998 for physician point-of-care use and in December 1999 for consumer use. Beckman Coulter will market the system to clinics, physician offices, and home health service providers...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.